Clinical trials: High Risk Bleeding
Placenta Previa Bleeding
High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa.
To assess the efficacy and safety of alternative magnesium sulfate regimens when used as single agent tocolytic therapy for prevention of preterm labour in patients with symptomatic placenta previa and subsequent changes in the…
- Trial name
- NCT04599868
- Testing
- Magnesium sulfate
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- Assiut University
Peptic Ulcer
Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
To evaluate if intravenous PPI infusion, when administered prior to endoscopy, hastens resolution of bleeding stigmata and thereby facilitates endoscopic examinations and reduces the need for endoscopic treatment.
- Trial name
- NCT00164866
- Testing
- Omeprazole
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Chinese University of Hong Kong
Subarachnoid Hemorrhage, Cerebral Aneurysm
Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution Magnetic Resonance (MR) Imaging Findings
To clarify whether amnesia after treatment of anterior communicating aneurysm (ACoA)is related to infarcts caused by occlusion or damage of the perforating artery of the ACoA, we used 3.0-T 3D high resolution MR imaging to…
- Conditions
- Subarachnoid Hemorrhage, Cerebral Aneurysm, Amnesia
- Trial name
- NCT01919775
- Volunteers
- 14 people
- Sponsor
- Tohoku University
Immune Thrombocytopenia
Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.
- Trial name
- NCT02834286
- Testing
- Rituximab, Eltrombopag, Dexamethasone
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Nonvalvular Atrial Fibrillation, Aspirin
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet…
- Conditions
- Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
- Trial name
- NCT07125417
- Testing
- Single Antiplatelet Therapy or No Therapy (Control), Non-Antithrombotic Therapy
- Where
- 21 sites in Japan
- Volunteers
- 500 people
- Sponsor
- OCEAN-SHD Study Group